


MedChem Russia 2019

4th Russian Conference on Medicinal Chemistry with international participants

June 10-14, 2019 Ekaterinburg, Russia

Abstract book



CONTENT

 Plenary Lectures Oral Presentations Poster Presentations Correspondent Presentations 			
		Author Index	619
		Partners and Sponsors	639

2-Oxindole as privileged structure for antiglaucomic and antidiabetic drug design: synthesis and biological activity

<u>Lozinskaya N.A.</u>^{1,2}, Zaryanova E.V.¹, Volkova M.S.¹, Efremov A.M.¹, Tsymlyakov M.D.¹, Bezsonova E.N.¹, Anikina L.V.², Beznos O.V.³, Babkov D.A.⁴, Sosonyuk S.E.¹, Proskurnina M.V.¹, Chesnokova N.B³ and Spasov A.A.⁴

¹Department of Chemistry, Lomonosov Moscow State University, 119234, Russia, Moscow, Leniskie Gory St., 1 ²Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432, Russia, Moscow Region, Chernogolovka, 1 Severniy Avenue ³Helmholtz Moscow Research Institute of Eye Diseases, Russia, Moscow Sadovaya-Chernogryazskaya str., 14/19 ⁴Research Institute of Pharmacology, Volgograd State Medical University, 400001, Russia, Volgograd, KIM St. 20

New amide-substituted oxindoles were synthesized using catalytic hydrogenation of corresponding nitro-derivatives and their biological activity was investigated [1]. The synthesis of new ligands of quinone reductase 2 (QR2, proposal MT3 receptor) [1-4] and kinase-3 β glycogen synthase (GSK3 β) [5] based on 2-oxindole scaffold was performed using condensation of isatin and 2-indolinone derivatives with appropriate compounds. The ability of oxindole-based QR2 ligands to reduce the intraocular pressure (IOP) was studied in vivo in normotensive rabbits. The lead compound was found to reduce IOP at 41% (more, then reference drug timolol (32%)) and had the long-lasting hypotensive effect (>6h). It was shown that 3-arylidene-substituted 2-oxindoles were effective inhibitors of kinase-3 β glycogen synthase and exhibit pronounced anti-diabetic activity under conditions of the glucose-tolerant test in vivo [5]. The lead compound showed moderate cytotoxicity in the micromolar range which creates a sufficient therapeutic window for the design of potential antidiabetic drugs based on this compound.

antiglaucomic agents

GSK3b inhibitors

X
RCONH
R2O
X
X=CH2NHCOR, CN, COOH
R1 = H,Alk
R = Alk, Ar

R2 = H, AlkCO

quinone reductase 2 (MT3) IC50 up to 200 nM intraocular pressure reduction up to 41%

IC50 up to 4.19 nM

References

RCONH

- [1] Zaryanova E.V., Ignatov A.A., Lozynskaya N.A. *Tetrahedron*, **2017**, *Vol. 73*, *P. 6887*–6893
- [2] Volkova M.S., Jensen K.C., Lozinskaya N.A., Sosonyuk S.E., Proskurnina M.V., Mesecar

A.D., Zefirov N.S. *Bioorganic and Medicinal Chemistry Letters,* **2012,** *Vol. 22, no.5, P. 7578*–7581

- [3] Zaryanova E.V., Lozinskaya N.A., Beznos O.V., Volkova M.S., Chesnokova N.B., Zefirov N.S. *Bioorganic and Medicinal Chemistry Letters*, **2017**, *Vol. 27*, *P. 3787–3793*.
- [4] Chesnokova N.B., Beznos O.V., Lozinskaya N.A., Volkova M.S., Zaryanova E.V., Zefirov N.S. Grygor'ev A.V. *Biochemistry, Supplemental Series B,* **2017**, *Vol. 11*, *no. 3*, *P. 272–278*[5] Lozinskaya N.A., Babkov D.A., Zaryanova E.V., Bezsonova E.N., Efremov A.M., Tsymlyakov M.D., Anikina L.V., Zakharyascheva O.Yu., Borisov A.V., Perfilova V.N., Tyurenkov I.N., Proskurnina M.V., Spasov A.A., *Bioorganic and Medicinal Chemistry,* **2019**, *in press*

Acknowledgments: This work was supported by the Russian Foundation for Basic Research (Project 17-03-01320)